Visual acuity and contrast sensitivity outcomes in Indian eyes undergoing photodynamic therapy with intravitreal injection of triamcinolone acetonide in age-related macular degeneration

Indian Journal of Ophthalmology

Volumn 55, Issue 3, 2007, Pages 207-211

  Kumar, Atul ^a,b   Sinha, Subijay ^a   Kumar, Vikram ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NONE   (India)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Intravitreal triamcinolone; Photodynamic therapy; Verteporfin

Indexed keywords

EID: 34247562343     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.31942     Document Type: Article

References (24)

1. Klein R, Klein BE, Linton KL. Prevalence of age related maculopathy: The beaver dam eye study. Ophthalmology 1992;99:933-43.
2. Mitchell P, Smith W, Altebo K, Wang JJ. Prevalence of age related maculopathy in Australia: The blue mountain eye study. Ophthalmology 1995;102:1450-60.
3. Vingerling JR, Diclemans IJ, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age related maculopathy in Rotterdam study. Ophthalmology 1995;102:205-10.
4. Nirmalan PK, Katz J, Robin AL, Tielsch JM, Namperumalsamy P, Kim R, et al. Prevalence of vitreo-retinal disorders in a rural population of south India. The Arvind Comprehensive eye study. Arch Ophthalmol 2004;122:581-6.
5. Ghazi NG, Jabbour NM, De La Cruz ZC, Green WR. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 2001;21:478-86.
6. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
7. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
8. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of Triamcinolone Acetonide. Am J Ophthalmol 1980;90:810-6.
9. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404.
10. Chandler DB, Rozakis G, de Juan E Jr, Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 1985;99:686-90.
11. Gillies MC, Sompson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al. A randomized clinical trail of a single dose of intravitreal Triamcinolone Acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003;121:667-73.
12. Jonas JB, Kreissing I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003;87:462-8.
13. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone Acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
14. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006;26:602-12.
15. Ergun E, Maar N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006;142:10-6.
16. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-45.
17. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: A comparative study. Br J Ophthalmal 2006;90:337-41.
18. Kaiser PK. Verteporfin therapy in combination with triamcinolone: Published studies investigating a potential synergisric effect. Curr Mod Res Opin 2005;21:705-13.
19. Arias L, Garda-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitroal triamcinolone in predominantly classic choroidal neovascularization one-year results of a randomized study. Ophthalmology 2006.
20. Hussain N, Das T, Rawal H, Kallukuri SB, Mohan Ram LS, Khanna R. Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularization. Indian J Ophthalmol 2006;54(4):247-50.
21. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
22. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-67.
23. Cui JZ, Kimura H, Spee C, Thumann G, Hinton DR, Ryan SJ. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol 2000;238:326-33.
24. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.